九強生物(300406.SZ)擬與國藥投資共同收購邁新生物95.55%股權
格隆匯12月6日丨九強生物(300406.SZ)公佈，公司擬與國藥投資共同採用支付現金方式購買德福二期、GL、杭州鼎暉、泰康人壽、廣州盈錠、王小亞、張雲、吳志全、夏榮強、緣朗投資合計持有的邁新生物95.55%的股權。其中，上市公司擬受讓交易對方合計持有的標的公司65.55%的股權，國藥投資擬受讓交易對方合計持有的標的公司30%的股權。此次重大資產購買的實施與國藥投資參股權收購的實施互為前提。
標的公司是中國腫瘤病理免疫組化診斷試劑的領先者，是一家生物醫藥高新技術企業。標的公司主導產品為免疫組化檢測儀器和系列試劑，營銷網絡遍佈全國。上市公司與標的公司同屬IVD行業，基於標的公司在免疫組化領域的領先性及專業性，此次整合可以推動雙方充分發揮各自比較優勢，對上市公司進一步提升公司檢測業務的服務水平和競爭實力具有重要意義。上市公司與標的公司技術及經驗共享，上市公司將在資金和市場資源方面為標的公司提供支持，同時拓寬業務範圍；標的公司則可以利用上市公司現有的客户資源基礎拓展更多的業務，從而雙方實現優勢互補，發揮協同效應，進一步提升上市公司綜合實力和核心競爭力。
通過此次重組，國藥集團的全資子公司國藥投資也將成為標的公司戰略投資人，將在多個方面加深標的公司與國藥集團的合作和協同。在戰略層面，有利於促進國企與民企在符合國家產業政策導向的領域互惠合作，充分激發各類市場主體活力，優化資源配置。在業務層面，國藥集團在大健康領域的深厚積累，尤其在渠道方面的成熟優勢，有利於標的公司拓寬銷售網絡和經營規模，進一步做大做強。在資本層面，引入國資股東將優化標的公司股權結構，在業務爭取和項目投資等方面帶來新的優勢。
此次交易前，九強生物主要從事生化臨牀體外診斷試劑的研發、生產和銷售。此次交易後，上市公司將進一步強化在體外診斷試劑領域的佈局。通過收購邁新生物，上市公司業務將覆蓋腫瘤細胞篩查和手術後腫瘤組織切片的臨牀診斷領域，擴充病理診斷試劑和儀器產品線，提升技術研發能力和營銷網絡佈局，鞏固上市公司在體外診斷產業的領軍地位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
